tiprankstipranks
Trending News
More News >
Contineum Therapeutics, Inc. Class A (CTNM)
NASDAQ:CTNM
US Market

Contineum Therapeutics, Inc. Class A (CTNM) Income Statement

Compare
206 Followers

Contineum Therapeutics, Inc. Class A Income Statement

Last quarter (Q3 2025), Contineum Therapeutics, Inc. Class A's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q3, Contineum Therapeutics, Inc. Class A's net income was $-12.79M. See Contineum Therapeutics, Inc. Class A’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21
Total Revenue
$ 0.00$ 50.00M$ 0.00$ 0.00
Gross Profit
$ -258.00K$ 50.00M$ -329.00K$ 0.00
Operating Expenses
$ 50.64M$ 66.08M$ 22.39M$ 28.65M
Depreciation and Amortization
$ 258.00K$ 195.00K$ 329.00K$ 325.00K
EBITDA
$ -42.00M$ 23.57M$ -23.54M$ -28.34M
Operating Income
$ -50.89M$ -16.08M$ -22.72M$ -28.65M
Other Income/Expenses
$ 8.64M$ 39.25M$ -1.53M$ -354.00K
Pretax Income
$ -42.26M$ 23.17M$ -24.25M$ -29.00M
Net Income
$ -42.26M$ 22.72M$ -24.25M$ -29.00M
Per Share Metrics
Basic EPS
$ -2.18$ 0.90$ -0.97$ -1.15
Diluted EPS
$ -2.18$ 0.90$ -0.97$ -1.15
Weighted Average Shares Outstanding
19.35M 25.28M 25.13M 25.13M
Weighted Average Shares Outstanding (Diluted)
19.35M 25.28M 25.13M 25.13M
Currency in USD

Contineum Therapeutics, Inc. Class A Earnings and Revenue History